Ulcerative colitis presenting with recurrent alternating bowel habits and rectal bleeding in a young female: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20252182Keywords:
Ulcerative colitis, Inflammatory bowel disease, Fecal calprotectin, Mesalamine, Early diagnosisAbstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that mostly affects the colon and rectum. The condition frequently causes symptoms such as diarrhoea, abdominal pain and rectal bleeding. Additionally, the delayed diagnosis is common because UC symptoms often mimic those of other conditions, such as haemorrhoids and IBS. This report underscores the need for timely diagnosis and intervention, based on clinical, endoscopic, and biomarker testing, including the use of fecal calprotectin. A 24-year-old female presented to her primary care provider with complaints of alternating bowel habits complaints, lower abdominal pain and rectal bleeding. She was initially misdiagnosed as having haemorrhoids and IBS with no systemic conditions suspected. Lab testing showed normal C-reactive protein (CRP <5 mg/l) and normal results on complete blood count (WBC 4.2 × 109/l, haemoglobin 13.2 g/dl, platelets 250×109/l, RBC 4.8×1012/l). Fecal calprotectin levels were notably high at 1035 µg/g; normal <50 µg/g). A colonoscopy revealed a diagnosis of distal proctitis that was classified as Mayo score 3. The first-line treatment included the use of mesalamine both orally and as a topical agent. Clinical improvement and reduced fecal calprotectin (34 µg/g) were reported during follow-up, reflecting gastrointestinal mucosal healing and a positive response to therapy. The usefulness of fecal calprotectin as a key biomarker in the evaluation of disease progression in UC is highlighted by this case. Appropriate diagnosis along with early mesalamine treatment contributed to symptoms relief and mucosal recovery. Immediate care is important in reducing complications and promoting patient recovery.
Metrics
References
Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. The Lancet. 2023;402(10401):571-84. DOI: https://doi.org/10.1016/S0140-6736(23)00966-2
Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis. Disease-a-Month. 2019;65(12):100851. DOI: https://doi.org/10.1016/j.disamonth.2019.02.004
Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. JAMA. 2023;330(10):951-65. DOI: https://doi.org/10.1001/jama.2023.15389
Segal JP, LeBlanc J-F, Hart AL. Ulcerative colitis: an update. Clinical Medicine. 2021;21(2):135-9. DOI: https://doi.org/10.7861/clinmed.2021-0080
Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343-56. DOI: https://doi.org/10.1016/j.cgh.2017.06.016
Al-Quorain AA. Extraintestinal manifestations of inflammatory bowel disease. Medknow; 2019: 65. DOI: https://doi.org/10.4103/sjmms.sjmms_111_19
Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118-32. DOI: https://doi.org/10.1053/j.gastro.2021.07.042
Wenzel A, Gold BD, Strople J. Laboratory evaluation of inflammatory bowel disease. Pediatric Inflammatory Bowel Dis. 2023:229-44. DOI: https://doi.org/10.1007/978-3-031-14744-9_18
Wang W, Cao W, Zhang S, Chen D, Liu L. The Role of Calprotectin in the Diagnosis and Treatment of Inflammatory Bowel Disease. International J Mol Sci. 2025;26(5):1996. DOI: https://doi.org/10.3390/ijms26051996
Limdi JK, Farraye FA. An update on surveillance in ulcerative colitis. Curr Gastroenterol Rep. 2018;20:1-12. DOI: https://doi.org/10.1007/s11894-018-0612-2
Malik A, Nadeem M, Javaid S, Malik MI, Enofe I, Abegunde AT. Estimating the optimum number of colon biopsies for diagnosing microscopic colitis: a systematic review. European J Gastroenterol Hepatolo. 2022;34(7):733-8. DOI: https://doi.org/10.1097/MEG.0000000000002355
Ng QX, Soh AYS, Loke W, Lim DY, Yeo W-S. The role of inflammation in irritable bowel syndrome (IBS). Journal of inflammation research. 2018:345-9. DOI: https://doi.org/10.2147/JIR.S174982
Nallajerla S, Ganta S. A comprehensive review on hemorrhoids a recto anal disorder. Pharmacology. 2021;1:270-82.
Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. United European Gastroenterol J. 2014;2(6):505-12. DOI: https://doi.org/10.1177/2050640614554217
Nakashima J, Patel P, Preuss CV. Mesalamine (USAN). StatPearls: StatPearls Publishing; 2024.
D’Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S. Long-term safety of approved biologics for ulcerative colitis. Expert Opin Drug Safety. 2020;19(7):807-16. DOI: https://doi.org/10.1080/14740338.2020.1773430
Choi D, Becker M, Ivanov M, Bhat S. Etrasimod: A sphingosine-1-phosphate receptor modulator for the treatment of ulcerative colitis. Ann Pharmacoth. 2024;58(10):1054-63. DOI: https://doi.org/10.1177/10600280231225770
Sarhan RSR, Marei YM, Marei YM. Evaluation of the diagnostic performance of estimated fecal calprotectin and serum intelectin-1 and C-reactive protein solo or in combination for differentiation between patients with query ulcerative colitis and irritable bowel syndrome. The Egyptian J Int Med. 2023;35(1):79. DOI: https://doi.org/10.1186/s43162-023-00263-8
Kristensen V, Røseth A, Ahmad T, Skar V, Moum B. Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis. Gastroenterol Res Pract. 2017;20(1):2098293. DOI: https://doi.org/10.1155/2017/2098293
Zamani H, Barzin G, Yousefinia M, Mohammadkhani A, Ostovaneh MR, Sharifi AH, et al. Diagnostic value of fecal calprotectin in patient with ulcerative colitis. Middle East J Digest Dis. 2013;5(2):76.
Chen F, Hu Y, Fan Y-H, Lv B. Clinical value of fecal calprotectin in predicting mucosal healing in patients with ulcerative colitis. Front Med. 2021;8:679264. DOI: https://doi.org/10.3389/fmed.2021.679264
Steinsbø Ø, Aasprong OG, Aabakken L, Karlsen LN, Grimstad T. Fecal calprotectin correlates with disease extent but remains a reliable marker of mucosal healing in ulcerative colitis. Official J American Coll Gastroenterol. 2009;7:9900.
Ye X, Wang Y, Wang HHX, Feng R, Ye Z, Han J, et al. Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. Therap Adv Gastroenterol. 2021;14:1756284821994741. DOI: https://doi.org/10.1177/1756284821994741
Güven B, İssi F, Sağ E, Buruk K, Çakır M. Impact of fecal calprotectin measurement for inflammatory bowel disease in children with alarm symptoms. Ped Inflam Bowel Dis. 2022;7:792. DOI: https://doi.org/10.4274/jpr.galenos.2021.99907
Kawakatsu S, Zhu R, Zhang W, Tang MT, Lu T, Quartino AL, et al. A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis. J Pharmacok Pharmacody. 2022;49(2):179-90. DOI: https://doi.org/10.1007/s10928-021-09789-2
Naegeli AN, Hunter T, Dong Y, Hoskin B, Middleton-Dalby C, Hetherington J, et al. Full, partial, and modified permutations of the Mayo score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients. Crohn's & colitis 360. 2021;3(1):37. DOI: https://doi.org/10.1093/crocol/otab007
Xu W, Liu F, Tang W, Gu Y, Zhong J, Cui L, et al. The Mayo endoscopic score is a novel predictive indicator for malignant transformation in ulcerative colitis: a long-term follow-up multicenter study. Front Surg. 2022;9:832219. DOI: https://doi.org/10.3389/fsurg.2022.832219
Md.Salma MDS, Y.Siva YS, Narendra JB. Case Report on Ulcerative Colitis in 16 year girl. World J Curr Med Pharma Res. 2020;6:287-90. DOI: https://doi.org/10.37022/wjcmpr.vi.154
Senbanjo IO, Oshikoya KA, Onyekwere CA, Abdulkareem FB, Njokanma OF. Ulcerative colitis in a Nigerian girl: A case report. BMC Research Notes. 2012;5:1-4. DOI: https://doi.org/10.1186/1756-0500-5-564
Vuyyuru SK, Jairath V, Hanžel J, Ma C, Feagan BG. Case report: medical management of acute severe ulcerative colitis. Gastroenterol Hepatol. 2023;19(10):621.
31. Scheller B, Winter C, Zamyad J, Felmlee K, Heard D. The Successful Management Of Ulcerative Colitis With A Nutritional Intervention: A Case Report. Integrat Med Clin J. 2019;18(5):40.
D’Amico F, Fiorino G, Solitano V, Massarini E, Guillo L, Allocca M, et al. Ulcerative colitis: Impact of early disease clearance on long‐term outcomes‐A multicenter cohort study. United European Gastroenterol J. 2022;10(7):775-82. DOI: https://doi.org/10.1002/ueg2.12288